TP53 Variants Linked to Childhood ALL, Poor Outcomes
MONDAY, Jan. 8, 2018 -- TP53 pathogenic variants are overrepresented in children with acute lymphoblastic leukemia (ALL) and are associated with worse outcomes, according to a study published online Jan. 4 in the Journal of Clinical Oncology.
Maoxiang Qian, Ph.D., from St. Jude Children's Research Hospital in Memphis, Tenn., and colleagues performed targeted sequencing of TP53 coding regions in 3,801 children from ALL clinical trials to examine the pattern, prevalence, and clinical relevance of TP53 variants in childhood ALL.
The researchers identified 49 unique non-silent rare TP53 coding variants in 77 of the patients sequenced (2 percent); 22 of the variants were classified as pathogenic. Compared with non-ALL controls, in ALL, TP53 pathogenic variants were significantly overrepresented (odds ratio, 5.2). The presence of TP53 pathogenic variants was associated with significantly older age at diagnosis (median age, 15.5 versus 7.3) and increased likelihood of having hypodiploid ALL (65.4 versus 1.2 percent). Inferior event-free and overall survival were seen in association with carrying germline TP53 pathogenic variants (hazard ratios, 4.2 and 3.9, respectively). Compared to children without pathogenic variants, children with pathogenic variants had a higher risk of second cancers (five-year cumulative incidence, 25.1 versus 0.7 percent).
"Loss-of-function germline TP53 variants predispose children to ALL and to adverse treatment outcomes of ALL therapy, particularly the risk of second malignant neoplasms," the authors write.
© 2020 HealthDay. All rights reserved.
Posted: January 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.